Ramadan fasting in insulin-treated patients is associated with potentially unfavourable changes in glucose metrics: A flash glucose monitoring (FGM) study

Diabetes Res Clin Pract. 2021 Feb:172:108592. doi: 10.1016/j.diabres.2020.108592. Epub 2020 Dec 9.

Abstract

Aim(s): Ramadan fasting (RF) can represent various challenges to glycaemic control especially in insulin-treated patients with diabetes. We aimed to assess the effect of RF on several glucose metrics using flash glucose monitoring (FGM).

Methods: Complete FGM data for 29-30 days before, during and after Ramadan were available for 40 patients with type 1 (n = 13) and type 2 diabetes (n = 27) on insulin (with or without oral hypoglycaemic) treatment. Indicators of mean glucose, glucose variability (GV) and time in different glycaemic ranges were analysed.

Results: RF was associated with increase in time in hyperglycaemia (38.5 ± 18.2 vs 48.7 ± 20.7%; P < 0.001) and decrease in time in hypoglycaemia (3.2 ± 2.8 vs 2.1 ± 2.1%; P = 0.003), and time in target range (56.3 ± 17.2 vs 47.9 ± 19.7%, P < 0.001). There were no significant differences in markers of GV with RF; however, RF was associated with a significant reduction in GV during the day but not night time with an increase in the ensuing non-fasting period.

Conclusions: In insulin-treated patients, RF is associated with an increase in time in hyperglycaemia, a reduced time in target range and nocturnal increase in GV, indicating a need for more refined management algorithms.

Keywords: Diabetes; Flash; Glucose; Insulin; Monitoring; Ramadan.

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose Self-Monitoring / methods*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Fasting / adverse effects*
  • Female
  • Glucose / analysis*
  • Humans
  • Hyperglycemia / epidemiology*
  • Hyperglycemia / etiology
  • Hypoglycemic Agents / adverse effects
  • Incidence
  • Insulin / adverse effects*
  • Islam*
  • Male
  • Middle Aged
  • United Arab Emirates / epidemiology

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glucose